Skip to main content
Clinical Trials/NCT05774054
NCT05774054
Completed
Not Applicable

The Impact of Early Norepinephrine Administration on Outcomes of Patients With Sepsis-induced Hypotension

Tanta University1 site in 1 country64 target enrollmentMay 1, 2021

Overview

Phase
Not Applicable
Intervention
Crystalloid
Conditions
Norepinephrine
Sponsor
Tanta University
Enrollment
64
Locations
1
Primary Endpoint
the required duration to achieve the target MAP
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Septic shock is defined as sepsis with persistent hypotension requiring vasopressors to maintain mean arterial pressure (MAP)≥ 65 mmHg and a serum lactate level of > 2 mmol/L (18 mg/dL) despite sufficient volume resuscitation

. Hypovolemia (both relative and absolute) and reduced vascular tone have a role in determining the severity of hypotension in septic shock

Detailed Description

Septic shock is defined as sepsis with persistent hypotension requiring vasopressors to maintain mean arterial pressure (MAP)≥ 65 mmHg and a serum lactate level of \> 2 mmol/L (18 mg/dL) despite sufficient volume resuscitation . Hypovolemia (both relative and absolute) and reduced vascular tone have a role in determining the severity of hypotension in septic shock . When mean arterial pressure (MAP) falls below a specific critical level organ blood flow is physiologically dependent on perfusion pressure. Fluid resuscitation and vasopressors have an influence on hypovolemia and the vascular tone in the early phase, as fluid resuscitation aims to correct hypovolemia and vasopressors-norepinephrine (NE)- as a first-line drug aiming to restore vascular tone to assure organ perfusion . Norepinephrine is both an alpha1- and beta1-agonist so it is able to increase vascular tone and contractility . Nevertheless, a large amount of fluids will increase the risk of fluid overload, which is a common complication during septic shock resuscitation * After the early phase, only fifty percent of patients respond to fluid administration, meaning that fluid treatment cannot boost cardiac output (CO) The current data indicate that the time from the onset of septic shock to the initiation of norepinephrine administration is a significant survival predictor; however, a suggestion for the optimal time to provide norepinephrine support was not explicitly expressed

Registry
clinicaltrials.gov
Start Date
May 1, 2021
End Date
March 10, 2023
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

tarek abdel hay mostafa

principle investigator

Tanta University

Eligibility Criteria

Inclusion Criteria

  • Adult patients aged from18 to 65 years old
  • had the diagnostic criteria for sepsis as the presence of infection
  • systemic manifestations of infection and signs of Hypoperfusion

Exclusion Criteria

  • Acute cerebral vascular event
  • Active cardiac conditions
  • Valvular heart diseases
  • Hypotension suspected to be due to another cause and comorbidities
  • Status asthmatics
  • Active hemorrhage
  • Pregnancy
  • Burn injury
  • Requirement for immediate surgery
  • Advanced-stage cancer

Arms & Interventions

A

patients received (30ml /kg) ringer's lactate solution after first presentation then norepinephrine was added when persistent mean arterial pressure (MAP)\> 65 mmHg despite adequate fluid resuscitation

Intervention: Crystalloid

B

patients received ( 30ml /kg) ringer's lactate solution after first presentation combined with norepinephrine infusion (0.05 mic/kg/min)

Intervention: noradrenaline

Outcomes

Primary Outcomes

the required duration to achieve the target MAP

Time Frame: 24 hours since the diagnosis of sepsis

time to achieve target mean arterial pressure over or equal to 65 mmHg once the diagnosis of sepsis is confirmed, is the target to stop fluid management.

Study Sites (1)

Loading locations...

Similar Trials